Trial
NCT01975298
A Study to Evaluate 2 Doses Of Oral Administration Of Laquinimod Compared to Interferon ß-1a Administered by Injection in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)
Phase IIIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Collaborators
—
Condition
Relapsing Remitting Multiple Sclerosis
Intervention
Laquinimod
Why stopped
Business Decision
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-11-09